Oil prices rise from over 1-mth low with Russia crude buyer sanctions in focus
Director Mirza Mansoor Raza of Sera Prognostics , INC. (NASDAQ:SERA) sold 234 shares of Class A Common Stock on July 7, 2025. The shares were sold at a price of $2.36, for a total transaction value of $552. The stock, which has shown significant volatility this year with a 71% decline over the past six months, currently trades at $2.72. According to InvestingPro analysis, the company appears fairly valued at current levels.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units. Following the transaction, Mirza Mansoor Raza directly owns 58,927 shares of Sera Prognostics, INC., a company with a market capitalization of $103 million that maintains a strong balance sheet with more cash than debt. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about SERA’s financial health and future prospects.
In other recent news, Sera Prognostics reported its Q1 2025 earnings, highlighting a narrower-than-expected EPS loss of -$0.20, compared to a forecast of -$0.27. However, revenue fell short of expectations, coming in at $38,000 against a projected $200,000, but it marked an improvement from zero revenue in the same quarter last year. Additionally, Sera Prognostics held its annual stockholders meeting, where Jane F. Barlow, M.D., and Mansoor Raza Mirza, M.D., were elected as Class I directors, and Ernst & Young LLP was ratified as the independent auditor for the fiscal year ending December 31, 2025. In leadership developments, the company appointed Lee Anderson as the new Chief Commercial Officer, bringing over three decades of healthcare leadership experience to drive the commercial expansion of Sera’s products. This appointment follows positive results from the company’s PRIME study, which has now entered the commercial phase. Moreover, Sera Prognostics continues to focus on strategic Medicaid and geographic expansion to enhance its market presence, as discussed during their earnings call. These recent developments reflect Sera’s ongoing efforts to strengthen its position in the healthcare diagnostics sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.